Pharmacy

The FINANCIAL -- Novo Nordisk on September 27 announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for the treatment of diabetes in China. Tresiba is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows for flexibility in day-to-day ...

More Articles ...

More Articles ...

The FINANCIAL -- Roche announced on September 22 that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people ...

Videos

Watch the video